share_log

Yunnan Botanee Bio-Technology Group Co.LTD's (SZSE:300957) Market Cap Dropped CN¥2.7b Last Week; Private Companies Bore the Brunt

Yunnan Botanee Bio-Technology Group Co.LTD's (SZSE:300957) Market Cap Dropped CN¥2.7b Last Week; Private Companies Bore the Brunt

云南博泰生物科技集团有限公司(深交所代码:300957)的市值上周下降了27亿人民币;私营企业遭受了最直接的影响
Simply Wall St ·  11/16 21:04

Key Insights

主要见解

  • The considerable ownership by private companies in Yunnan Botanee Bio-Technology GroupLTD indicates that they collectively have a greater say in management and business strategy
  • The top 2 shareholders own 58% of the company
  • Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
  • 在云南植物生物技术集团有限公司中,私人公司拥有相当大的所有权,这表示他们在管理和商业策略上有更大的发言权
  • 该公司前2大股东拥有该公司58%的股份。
  • 通过分析师预测数据和所有权研究,您可以更好地评估公司未来的业绩。

Every investor in Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 54% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

云南植物生物技术集团有限公司(SZSE:300957)中的每位投资者都应该注意最强大的股东群体。 拥有公司最多股份的群体,准确地说约占公司股份的54%,是私人公司。 换句话说,如果股价上涨(或下跌),该群体将获得最大好处(或蒙受最大损失)。

As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥2.7b.

作为结果,私人公司作为一个整体在上周承受了最大的损失,市值下降了27亿人民币。

In the chart below, we zoom in on the different ownership groups of Yunnan Botanee Bio-Technology GroupLTD.

在下面的图表中,我们将重点放在云南百灵生物科技集团有限公司的不同所有权群体上。

big
SZSE:300957 Ownership Breakdown November 17th 2024
SZSE:300957 所有权拆分 2024年11月17日

What Does The Institutional Ownership Tell Us About Yunnan Botanee Bio-Technology GroupLTD?

机构持股告诉我们关于云南百灵生物科技集团有限公司的什么?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。

We can see that Yunnan Botanee Bio-Technology GroupLTD does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Yunnan Botanee Bio-Technology GroupLTD's earnings history below. Of course, the future is what really matters.

我们可以看到云南百灵生物科技集团有限公司确实有机构投资者;并且他们持有公司股票的相当比例。这意味着那些机构的分析师们已经看过这支股票,而且他们喜欢它。但就像其他人一样,他们也可能是错的。 如果多家机构同时改变对一只股票的看法,你就可能看到股价快速下跌。因此,值得查看一下云南百灵生物科技集团有限公司的历史收入情况。当然,未来才是真正重要的。

big
SZSE:300957 Earnings and Revenue Growth November 17th 2024
深圳证券交易所: 300957盈利和营业收入增长2024年11月17日

We note that hedge funds don't have a meaningful investment in Yunnan Botanee Bio-Technology GroupLTD. Our data shows that Kunming Nuona Technology Co., Ltd. is the largest shareholder with 46% of shares outstanding. In comparison, the second and third largest shareholders hold about 12% and 6.6% of the stock. Furthermore, CEO Zhenyu Guo is the owner of 2.6% of the company's shares.

我们注意到,对云南博智生物科技集团有限公司(Yunnan Botanee Bio-Technology GroupLTD)的对冲基金投资不具有重要意义。我们的数据显示,昆明诺纳科技有限公司是最大的股东,持有46%的股份。相比之下,第二和第三大股东持有约12%和6.6%的股份。此外,CEO郭振宇拥有公司2.6%的股份。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

为了使我们的研究更有趣,我们发现前2名股东拥有该公司的大部分所有权,这意味着他们足够强大,可以影响公司的决策。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

虽然仔细研究公司的机构持股数据是有意义的,但研究分析师对该股票的看法也是有意义的。有相当数量的分析师在跟踪该股票,因此了解他们对于未来发展的总体看法可能会有所帮助。

Insider Ownership Of Yunnan Botanee Bio-Technology GroupLTD

云南博智生物科技集团有限公司(Yunnan Botanee Bio-Technology GroupLTD)的内部持股情况

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

虽然“内部人士”的明确定义具有主观性,但几乎所有人都认为董事会成员是内部人士。公司管理业务,但首席执行官即使是董事会成员,也要向董事会负责。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。

Shareholders would probably be interested to learn that insiders own shares in Yunnan Botanee Bio-Technology Group Co.LTD. This is a big company, so it is good to see this level of alignment. Insiders own CN¥547m worth of shares (at current prices). It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.

股东们可能会对知道内部持有云南宝天生物科技集团股份感兴趣。这是一家大公司,所以看到这种程度的协调是好事。内部持有价值5,4700万元人民币的股份(按当前价格计算)。看到内部人员做出的这种投资是件好事。您可以在这里查看这些内部人员最近是否一直在买入。

General Public Ownership

一般大众所有权

With a 23% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Yunnan Botanee Bio-Technology GroupLTD. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

拥有23%股权的普通公众,主要由个人投资者组成,在云南宝天生物科技集团LTD的影响力较大。虽然这种所有权规模可能不足以影响对他们有利的政策决定,但他们仍然可以对公司政策产生集体影响。

Private Equity Ownership

股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。

With a stake of 12%, private equity firms could influence the Yunnan Botanee Bio-Technology GroupLTD board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

拥有12%股份的股权投资公司可能会影响云南博澄生物科技集团有限公司的董事会。一些投资者可能会受到鼓舞,因为股权投资公司有时能够鼓励制定能够帮助市场看到公司价值的战略。另一方面,这些持有者可能在将其上市后退出投资。

Private Company Ownership

私有公司的所有权

We can see that Private Companies own 54%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我们可以看到,私人公司拥有发行股份的54%。值得进一步深入研究。如果关联方,如内部人士,在其中一家私人公司中拥有利益,这应在年度报告中披露。私人公司可能还对该公司有战略利益。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Yunnan Botanee Bio-Technology GroupLTD has 4 warning signs we think you should be aware of.

我发现查看一家公司的实际股东非常有趣。但要真正深入了解,我们也需要考虑其他信息。以风险为例 - 云南博澄生物科技集团有限公司有4个警告信号,我们认为您应该注意。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最终,未来最重要。您可以在这份关于该公司分析师预测的免费报告中获取有关信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发